Syncromune Appoints Dr. Stephen P. Dale as Chief Medical Officer
Syncromune announced the appointment of Stephen P. Dale, M.D., as Chief Medical Officer on January 6, 2026.135
Dr. Dale has over 20 years of global oncology R&D experience, previously serving as Head of R&D and CMO at Kura Oncology, and in senior roles at Kyowa Kirin and AstraZeneca.14
He will lead clinical development of SYNC-T, an in situ immunotherapy platform for solid tumors, including Phase 2 progression of SV-102.15
Syncromune is a clinical-stage biopharmaceutical company focused on SYNC-T for solid tumor cancers.15
Quotes from leadership highlight Dr. Dale's expertise in advancing therapies and prioritizing patient safety and impact.1
Sources:
1. https://www.biospace.com/press-releases/syncromune-continues-to-strengthen-executive-and-clinical-leadership-with-appointment-of-dr-stephen-p-dale-m-d-as-chief-medical-officer
3. https://firstwordpharma.com/river/type/People%20News
4. https://www.thepharmaletter.com/biotechnology/former-kura-oncology-cmo-stephen-dale-joins-syncromune